For triple positive metastatic breast cancer, is there a role for aromatase inhibitor + CDK 4/6 inhibitor with Her2 directed therapy in a patient that refuses chemotherapy?

Patient defers chemotherapy. She is currently on anastrozole/Herceptin and perjeta with a response but it is suboptimal. I would like to add a CDK 4/6 inhibitor.

Answer from: Medical Oncologist at Academic Institution

Recommend the PATINA trial, a randomized Phase 3 study. open to women or men with HR+, HER2+ metastatic breast cancer following completion of induction with anti-HER2-based chemotherapy. Would not recommend this approach outside of a clinical trial at this time, however.

Comments

Medical Oncologist at Warren Alpert Medical School of Brown University
I agree with recommending participation in this tr...

Medical Oncologist at Siri Onclogy and hematology Infusion Service
What is a suboptimal response? If she has responde...

Answer from: Medical Oncologist at Community Practice

I personally would not do it outside a clinical trial. I, on the other hand, would consider upgrading her endocrine treatment to fulvestrant.

Please select the option that best describes you:

For triple positive metastatic breast cancer, is there a role for aromatase inhibitor + CDK 4/6 inhibitor with Her2 directed therapy in a patient that refuses chemotherapy?

Related Questions